Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis

• DOI: 10.3892/mco.2020.2190
• Publication Date: 2020-12-16T07:09:44Z
• Authors: Hiroyuki Iwasaki; Soji Toda; Daisuke Murayama; Shin Kato; Ai Matsui
• Keywords: Lenvatinib; Discontinuation; Anaplastic thyroid cancer; Mediastinitis

Tyrosine kinase inhibitors (TKIs) were first approved for treating radioactive iodine‑refractory differentiated thyroid cancer (DTC) and anaplastic (ATC) 5 years ago. Among them, lenvatinib has a high response rate become the first‑line drug cancer. Although it rate, is also characterized by frequency of adverse events (AEs). AEs previously reported in phase II study occurred after practical application TKI therapy. However, type that significantly different. The present investigated real‑world setting examined their relationship with prognosis. Between June 2015 May 2020, 111 patients (79 DTC 32 ATC) treated lenvatinib. An investigation AEs, including fatal events, revealed fistula formation or severe tumor regrowth discontinuation treatment was an AE associated poor In total, 11 ATC (34.4%) 7 (8.9%) developed skin fistula. mortality among these 38.9% (7/18), three deaths caused major bleeding four attributable to mediastinitis pneumonia. group, irreversible all who required withdrawal because died. Conversely, overall survival longer hand‑foot syndrome (HFS). Therefore, illustrated although therapy can result requiring dose reduction discontinuation, HFS appearance portends good prognosis